Get started
Author

Sari Alon

Observed name: Alon, Sari
Observed institution: Protalix BioTherapeutics (Israel)
OpenAlex ID: A5104033760
Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1‐year Phase 1/2 clinical trial
2019 · Raphael Schiffmann, Ozlem Goker‐Alpan, et al. · Journal of Inherited Metabolic Disease · 148
PDF
Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study
2023 · Eric L Wallace, Ozlem Goker-Alpan, et al. · Journal of Medical Genetics · 56
PDF
Immunogenicity of glycans on biotherapeutic drugs produced in plant expression systems—The taliglucerase alfa story
2017 · Bonita Rup, Sari Alon, et al. · PLoS ONE · 56
PDF
Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study
2023 · Aleš Linhart, Gabriela Dostálová, et al. · Orphanet Journal of Rare Diseases · 40
PDF
Long-term safety and efficacy of pegunigalsidase alfa: A multicenter 6-year study in adult patients with Fabry disease
2023 · Derralynn Hughes, Derlis Gonzalez, et al. · Genetics in Medicine · 29
PDF
Long-term efficacy and safety results of taliglucerase alfa through 5 years in adult treatment-naïve patients with Gaucher disease
2016 · Ari Zimran, Gloria Durán, et al. · Blood Cells Molecules and Diseases · 29
PDF
Novel Orally Administered Recombinant Anti-TNF Alpha Fusion Protein for the Treatment of Ulcerative Colitis
2020 · Einat Almon, Yoseph Shaaltiel, et al. · Journal of Clinical Gastroenterology · 28
An oral administration of a recombinant anti-TNF fusion protein is biologically active in the gut promoting regulatory T cells: Results of a phase I clinical trial using a novel oral anti-TNF alpha-based therapy
2017 · Einat Almon, Tawfik Khoury, et al. · Journal of Immunological Methods · 25
A phase III , open‐label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies
2024 · Myrl Holida, Aleš Linhart, et al. · Journal of Inherited Metabolic Disease · 22
Preclinical and first-in-human evaluation of PRX-105, a PEGylated, plant-derived, recombinant human acetylcholinesterase-R
2015 · Jacob Atsmon, Einat Brill-Almon, et al. · Toxicology and Applied Pharmacology · 22
Pharmacokinetics of Novel Plant Cell-Expressed Taliglucerase Alfa in Adult and Pediatric Patients with Gaucher Disease
2015 · Richat Abbas, Glen Park, et al. · PLoS ONE · 11
PDF
Switching from agalsidase alfa to pegunigalsidase alfa for treating Fabry disease: One year of treatment data from BRIDGE, a phase III open label study
2020 · Ales Linhart, Gabriela Dostalova, et al. · Molecular Genetics and Metabolism · 8
Once every 4 weeks - 2 mg/kg of pegunigalsidase alfa for treating Fabry disease Preliminary results of a phase 3 study
2019 · Myrl D. Holida, John Bernat, et al. · Molecular Genetics and Metabolism · 8
eP149: Safety and efficacy of pegunigalsidase alfa, every 4 weeks, in Fabry disease: Results from the phase 3, open-label, BRIGHT study
2022 · John Bernat, Myrl Holida, et al. · Genetics in Medicine · 7
Pegunigalsidase alfa for the treatment of Fabry disease: Preliminary results from a phase III open label, switch over study from agalsidase alfa
2019 · Ales Linhart, Kathy Nicholls, et al. · Molecular Genetics and Metabolism · 4
Long-term safety and efficacy of pegunigalsidase alfa administered every 4 weeks in patients with Fabry disease: Two-year interim results from the ongoing phase 3 BRIGHT51 open-label extension study
2023 · John Bernat, Myrl D. Holida, et al. · Molecular Genetics and Metabolism · 2
739 - A Novel Orally Administered Recombinant Anti-TNF Alpha Fusion Protein for the Treatment of Mild to Moderate Ulcerative Colitis: Results of a Phase 2A Clinical Trial Showing Promising Results
2018 · Einat Almon, Eran Goldin, et al. · Gastroenterology · 2
Pegunigalsidase alfa, a novel PEGylated ERT for Fabry disease: Two-year safety and efficacy follow up
2018 · Derralynn Hughes, Pilar Giraldo, et al. · Molecular Genetics and Metabolism · 2
PRX-102 for treating Fabry disease: immunogenicity and PK results from a phase 1-2 study
2017 · David Warnock, Derralynn Hughes, et al. · Molecular Genetics and Metabolism · 2
Novel treatment for Fabry disease: IV administration of plant derived alpha-gal-A enzyme safety and efficacy interim report
2016 · Derralynn Hughes, Simeon Boyd, et al. · Molecular Genetics and Metabolism · 2
Tolerability of pegunigalsidase alfa across the clinical program: Integrated analysis of infusion-related reactions by prior enzyme replacement therapy
2024 · Ankit Mehta, Eric Wallace, et al. · Molecular Genetics and Metabolism · 1
Tolerability of pegunigalsidase alfa across the clinical program: Integrated analysis of infusion-related reactions by dosing regimens
2024 · Derralynn Hughes, John Bernat, et al. · Molecular Genetics and Metabolism · 1
Assessment of immunogenicity from the pegunigalsidase alfa clinical trial program: Integrated analysis of de novo and treatment-boosted anti-drug antibodies
2024 · John Bernat, Derralynn Hughes, et al. · Molecular Genetics and Metabolism · 1
First results of a head-to-head trial of pegunigalsidase alfa vs. agalsidase beta in Fabry disease: 2 year results of the phase 3 randomized, double-blind, BALANCE study
2023 · Eric Wallace, Wilcox Goker-Alpan, et al. · Molecular Genetics and Metabolism · 1
eP148: Long-term safety and efficacy of pegunigalsidase alfa: A multicenter extension study in adult patients with Fabry disease
2022 · Derlis Gonzalez, Gustavo Maegawa, et al. · Genetics in Medicine · 1
PDF
Works count: 53
Citation count: 512
H-index: 11
I10-index: 11
Year
Topic
Type